RTP Mobile Logo

Monday, June 4, 2018, Chicago, IL, 7:00 PM – 9:30 PM

Consensus or Controversy? Clinical Investigators Provide Perspectives on Practical Issues and Ongoing Research Related to the Management of Breast Cancer

Event Details

Location:
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Time:
6:30 PM – 7:00 PM (Central Time) — Registration and Dinner Buffet
7:00 PM – 9:30 PM (Central Time) — Educational Meeting

Meeting Room:
Grand Ballroom (Level 2)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
 
Faculty:
Harold J Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Sara A Hurvitz, MD
Associate Professor of Medicine
Director, Breast Oncology Program, Division of Hematology/Oncology
University of California, Los Angeles
Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit
Los Angeles, California
Co-Director, Santa Monica-UCLA Outpatient Oncology Practices
Santa Monica, California


George W Sledge Jr, MD
Professor of Medicine
Chief, Division of Oncology
Department of Medicine
Stanford University School of Medicine
Stanford, California

Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Additional faculty to be announced

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Lilly and Merck.

Agenda

6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:30 PM — Educational Meeting

This CME symposium will employ Research To Practice’s popular Consensus or Controversy? format to explore practical issues and ongoing research surrounding the management of early and advanced breast cancer. Six renowned investigators will serve as the faculty, and RTP president and medical oncologist Dr Neil Love will serve as the moderator. Leading up to the program, RTP will recruit a cadre of practicing general oncologists to provide challenging cases of patients with various forms of breast cancer from their practices. Each faculty member will then be asked to complete a survey centered on selected cases and related management issues, and the responses from all 6 experts will be summarized and graphically presented at the live event to illustrate the group’s perspectives. The symposium will be divided into 6 topic modules, each featuring the presentation and discussion of faculty survey results and a faculty member-led review of data and ongoing clinical research. Clinicians in attendance will use networked iPads® to complete a premeeting survey including a number of the same questions posed to the faculty. The results from the 2 cohorts will be juxtaposed to foster additional debate and elucidate knowledge and practice gaps that may exist within the community.

A detailed agenda will be made available in the coming weeks.

CE Information

Target Audience:
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.

Learning Objectives and Goals:
At the conclusion of this activity, participants should be able to:

  • Compare and contrast expert perspectives on breast cancer treatment recommendations, and use this information to refine or validate existing management strategies.
  • Consider published data to guide the use of biomarkers and genomic classifiers to assess risk and customize therapy for patients with hormone receptor-positive breast cancer in the neoadjuvant, adjuvant and extended-adjuvant settings.
  • Appraise available and emerging research evidence to individualize the selection and duration of neoadjuvant, adjuvant and/or extended adjuvant therapy for patients with HER2-overexpressing early breast cancer.
  • Implement a long-term clinical plan for the management of metastatic HER2-positive breast cancer, incorporating existing and investigational targeted treatments.
  • Develop an evidence-based algorithm for the treatment of advanced hormone receptor-positive pre- and postmenopausal breast cancer, including endocrine, biologic and chemotherapeutic agents.
  • Consider published research and patient preferences in the selection and sequencing of available and investigational therapeutic agents for metastatic ER/PR-negative, HER2-negative breast cancer.
  • Develop an understanding of the mechanisms of action, available data and potential clinical roles of investigational compounds in preparation for their potential introduction into future clinical practice.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Lilly and Merck.

Location

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

Directions:
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 

Registration

This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.